FDA Panel OKs Celltrion Biosimilar Of Janssen's Remicade
After a grueling debate, an independent panel on Tuesday advised the U.S. Food and Drug Administration to approve Celltrion's copy of Janssen Biotech's blockbuster immunosuppressant Remicade, the latest step forward for...To view the full article, register now.
Already a subscriber? Click here to view full article